Index of reports
> Cases with Fatigue (87)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Velcade (Bortezomib) where reactions include fatigue. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 87 Next >>
Possible Velcade side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27
Patient: male, weighing 93.4 kg (205.5 pounds)
Reactions: Confusional State, Fatigue, Pseudomembranous Colitis, Asthenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Dosage: 2.95 mg, cyclic
Indication: Multiple Myeloma
Start date: 2011-02-07
End date: 2011-03-03
Decadron
Dosage: unk
Indication: Multiple Myeloma
Other drugs received by patient: Zofran; Cipro / 00042702 /; Duragesic-100; Armodafinil; Xanax; Morphine Sulfate; Miralax; Valtrex
Possible Velcade side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22
Patient: female
Reactions: Fatigue, Neuropathy Peripheral
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Doxorubicin HCL
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Velcade side effects in female
Reported by a physician from United States on 2012-08-10
Patient: female
Reactions: Fatigue, Pain, Protein Total Increased, Coombs Test Positive, Constipation, Blood Viscosity Increased
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in 50 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-09
Patient: 50 year old female
Reactions: Fatigue, Injection Site Pain, Constipation
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in 55 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-03
Patient: 55 year old female
Reactions: Thrombosis, Weight Increased, Fatigue, Neuropathy Peripheral, Hypertension
Drug(s) suspected as cause:
Thalidomide
Velcade
Possible Velcade side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: maintenance
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Rituximab
Dosage: maintenance
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Velcade side effects in 54 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-27
Patient: 54 year old male
Reactions: Neuropathy Peripheral, Fatigue
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in 61 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-26
Patient: 61 year old male
Reactions: Neuropathy Peripheral, Fatigue, Gastrointestinal Disorder, Decreased Appetite
Drug(s) suspected as cause:
Velcade
Indication: Multiple Myeloma
Start date: 2009-08-01
End date: 2010-06-01
Revlimid / Dexamethasone
Indication: Multiple Myeloma
Start date: 2009-08-01
Possible Velcade side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18
Patient:
Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Velcade
Dosage: 1.3 milligram/sq. meter
Indication: Multiple Myeloma
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Revlimid
Dosage: 15 milligram
Administration route: Oral
Cyclophosphamide
Dosage: 500 milligram/sq. meter
Indication: Multiple Myeloma
Velcade
Dosage: 1.3 milligram/sq. meter
Dexamethasone
Dosage: 40 milligram
Indication: Multiple Myeloma
Possible Velcade side effects in 62 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18
Patient: 62 year old female
Reactions: Injection Site Erythema, Fatigue, Asthenia, Decreased Appetite
Drug(s) suspected as cause:
Velcade
Dosage: sq
Indication: Multiple Myeloma
Revlimid
Possible Velcade side effects in female
Reported by a consumer/non-health professional from United States on 2012-07-17
Patient: female
Reactions: Fatigue, Pain, Protein Total Increased, Constipation, Coombs Test Positive, Blood Viscosity Increased
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in
Reported by a consumer/non-health professional from United States on 2012-07-16
Patient:
Reactions: Vomiting, Dyspnoea, Nausea, Pyrexia, Cardiomyopathy, Renal Failure Chronic, Weight Increased, Tumour Lysis Syndrome, Fatigue, Respiratory Failure, Vitamin B12 Deficiency, Alopecia, Ejection Fraction Decreased, Arteriosclerosis Coronary Artery, Respiratory Tract Infection, Cardiac Failure Congestive
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Multiple Myeloma
Start date: 2007-11-05
End date: 2007-12-03
Dexamethasone
Dosage: 20 mg, cyclic
Indication: Multiple Myeloma
Other drugs received by patient: OS-CAL / 00108001 /; Colace; Nexium; Synthroid; Allopurinol; Lasix; Lisinopril; Lovenox; Aspirin
Possible Velcade side effects in female
Reported by a consumer/non-health professional from United States on 2012-07-16
Patient: female, weighing 59.0 kg (129.7 pounds)
Reactions: Vomiting, Fatigue, Nausea, Oesophagitis, Dehydration, Urinary Tract Infection, Hypotension, Systemic Inflammatory Response Syndrome, Lobar Pneumonia, Renal Failure Acute
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Other drugs received by patient: Prilosec; Colace; Prozac; Fentanyl; Potassium Chloride; Vicodin; Iron; Atenolol; Synthroid; Warfarin Sodium
Possible Velcade side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-12
Patient: female
Reactions: Death, Neuropathy Peripheral, Fatigue, Diarrhoea, Colitis Microscopic
Adverse event resulted in: death, disablity
Drug(s) suspected as cause:
Velcade
Dosage: 2.4 mg, unk
Indication: Product Used FOR Unknown Indication
Start date: 2009-12-01
End date: 2010-09-01
Revlimid
Dosage: 25 mg, qd
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2009-04-01
End date: 2010-12-01
Revlimid
Dosage: 25 mg, qd
Administration route: Oral
Start date: 2011-01-01
End date: 2011-03-01
Other drugs received by patient: Aredia; Dexamethasone Sodium Posphate
Possible Velcade side effects in female
Reported by a physician from United States on 2012-07-06
Patient: female, weighing 92.0 kg (202.4 pounds)
Reactions: White Blood Cell Count Decreased, Dyspnoea, Anaemia, Febrile Neutropenia, Muscular Weakness, Acidosis, Renal Failure Chronic, Fatigue, Sepsis, Platelet Count Decreased, Hypoxia, Neutrophil Count Decreased, Lymphocyte Count Decreased, Decreased Appetite
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Myeloid Leukaemia
Start date: 2012-05-02
End date: 2012-06-06
Decitabine
Dosage: 20 mg/m2, cyclic
Indication: Acute Myeloid Leukaemia
Start date: 2012-05-02
End date: 2012-06-08
Possible Velcade side effects in female
Reported by a consumer/non-health professional from United States on 2012-07-06
Patient: female
Reactions: Back Pain, Dyspnoea, Pain in Extremity, Bone Pain, Anxiety, Fatigue, Activities of Daily Living Impaired, Coordination Abnormal, Depression, Asthenia
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Velcade
Dosage: on days 1 and 8
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Cyclophosphamide
Velcade
Dosage: on days 1 and 8
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: maintenance
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: maintenance
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Velcade
Dosage: on days 1 and 8
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Indication: B-Cell Lymphoma
Possible Velcade side effects in male
Reported by a consumer/non-health professional from United States on 2012-07-05
Patient: male
Reactions: Fatigue, Neuropathy Peripheral, Diarrhoea, Dizziness, Asthenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in female
Reported by a physician from United States on 2012-07-05
Patient: female
Reactions: Death, Neuropathy Peripheral, Fatigue, Colitis Microscopic
Adverse event resulted in: death, disablity
Drug(s) suspected as cause:
Revlimid
Dosage: 25 milligram
Administration route: Oral
Start date: 2011-01-01
End date: 2011-03-01
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2009-04-01
End date: 2010-12-01
Velcade
Dosage: 2.4 milligram
Start date: 2009-12-01
End date: 2010-09-01
Other drugs received by patient: Dexamethasone Sodium Phosphate; Aredia
Possible Velcade side effects in 62 year old male
Reported by a physician from United Kingdom on 2012-07-03
Patient: 62 year old male
Reactions: Fatigue, Diarrhoea, Nausea, Pulmonary Embolism, Electrolyte Imbalance, Lower Respiratory Tract Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 160 mg;;po
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2010-01-05
End date: 2010-02-26
Velcade
Dosage: 2.5 mg;;iv, 1.3 mg;;iv
Indication: Multiple Myeloma
Start date: 2010-03-29
End date: 2010-03-29
Velcade
Dosage: 2.5 mg;;iv, 1.3 mg;;iv
Indication: Multiple Myeloma
Start date: 2010-01-05
Other drugs received by patient: Acyclovir; Fluconazole; Dexamethasone; Fentanyl; Furosemide; Lansoprazole; Melphalan Hydrochloride; Vincristine; Doxorubicin HCL; Metformin Hydrochloride; Pioglitazone; Cyclophosphamide; Thalidomide; Glimepiride
Possible Velcade side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29
Patient: male, weighing 128.1 kg (281.8 pounds)
Reactions: Musculoskeletal Pain, Anaemia, Mental Status Changes, Multiple Myeloma, Hypercalcaemia, Osteonecrosis, Fatigue, Gait Disturbance, Thrombocytopenia, Pathological Fracture
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Cytoxan
Revlimid
Indication: Product Used FOR Unknown Indication
Velcade
Dosage: unk
Start date: 2012-05-03
Dexamethasone
Indication: Product Used FOR Unknown Indication
Velcade
Dosage: 1.3 mg, cyclic
Indication: Multiple Myeloma
Start date: 2012-03-07
End date: 2012-04-23
Etoposide
Indication: Product Used FOR Unknown Indication
Other drugs received by patient: Metoprolol Succinate; Ramipril; Duloxetime Hydrochloride; Glucophage; Catapres / 00171101 /; Allopurinol; Cymbalta; Percocet; Zometa; Ativan; Ascriptin A / D
Possible Velcade side effects in female
Reported by a physician from United States on 2012-06-28
Patient: female
Reactions: Fatigue, Pain, Protein Total Increased, Coombs Test Positive, Constipation, Blood Viscosity Increased
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in 28 year old female
Reported by a physician from United States on 2012-06-28
Patient: 28 year old female
Reactions: Vanishing Bile Duct Syndrome, Fatigue, Liver Function Test Abnormal
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in 62 year old female
Reported by a physician from United States on 2012-06-28
Patient: 62 year old female
Reactions: Fatigue, Pericarditis, Pneumonia Cytomegaloviral
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-27
Patient:
Reactions: Nausea, Chills, Anaemia, Constipation, Neuropathy Peripheral, Fatigue, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Rituximab
Dosage: maintenance
Velcade
Dosage: on days 1 and 8
Indication: Chronic Lymphocytic Leukaemia
Velcade
Dosage: on days 1 and 8
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Velcade
Dosage: on days 1 and 8
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Doxorubicin HCL
Dosage: on day 1
Rituximab
Dosage: on day 1
Cyclophosphamide
Indication: B-Cell Lymphoma
Cyclophosphamide
Doxorubicin HCL
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Possible Velcade side effects in female
Reported by a consumer/non-health professional from United States on 2012-06-22
Patient: female
Reactions: Back Pain, Dyspnoea, Pain in Extremity, Bone Pain, Anxiety, Fatigue, Activities of Daily Living Impaired, Coordination Abnormal, Depression, Asthenia
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in
Reported by a physician from United States on 2012-06-22
Patient:
Reactions: Fatigue, Blood Count Abnormal
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in 72 year old female
Reported by a consumer/non-health professional from United States on 2012-06-21
Patient: 72 year old female, weighing 59.0 kg (129.7 pounds)
Reactions: Vomiting, Fatigue, Nausea, Urinary Tract Infection, Dehydration, Hypotension, Systemic Inflammatory Response Syndrome, Lobar Pneumonia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in female
Reported by a consumer/non-health professional from United States on 2012-06-20
Patient: female, weighing 92.0 kg (202.4 pounds)
Reactions: White Blood Cell Count Decreased, Dyspnoea, Anaemia, Muscular Weakness, Acidosis, Renal Failure Chronic, Fatigue, Sepsis, Platelet Count Decreased, Hypoxia, Neutrophil Count Decreased, Lymphocyte Count Decreased
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Decitabine
Dosage: 20 mg/m2, cyclic
Indication: Acute Myeloid Leukaemia
Start date: 2012-05-02
End date: 2012-06-08
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Myeloid Leukaemia
Start date: 2012-05-02
End date: 2012-06-06
Page 1 Next >>
|